When it comes to its investment in Japan's Chugai Pharmaceutical, Roche CEO Severin Schwan says he likes things just the way they are
Life Technologies is fielding buyout offers from a competitor and a group of private equity giants, but that hasn't stopped the company from making acquisitions of its own, now snatching up a Korean distributor of reagents and lab instruments.
China revamped, renamed and promoted its drug regulator recently after a series of embarrassing disclosures last year by Chinese media about toxic capsules and cooking oil used in antibiotics. But no sooner had the new ministerial-level agency made its debut then state TV in China reported a new scandal that affected one of its larger drugmakers.
India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry.
India's Supreme Court is keeping the pressure on Western drugmakers. Just days after invalidating a patent for Novartis' cancer drug Glivec, it has said a generic drugmaker there is free, for now, to proceed with its cheap knockoff of Merck's vaunted diabetes drugs.
Pfizer CEO Ian Read has given yet another glimpse into the future of the drugmaker as he shapes it into a more efficient pharmaceutical operation. In a disappointing disclosure to those who look for more spinoffs, he said Pfizer will hold onto its consumer health business.
With a clear eye toward expanding its focus on emerging markets, Smith & Nephew this week announced plans to snatch up its long-time Brazilian-based distributor.
Daktari Diagnostics is scaling up its manufacturing presence, planning to spend $15 million to build a plant in Scotland that will manufacture point-of-care HIV tests.
Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos. Reuters sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.
Abbott Laboratories is largely focused on medical devices and diagnostics since spinning its innovative drugs business off into AbbVie, but Reuters reports the company is bidding on Brazilian drugmaker Aché Laboratorios Farmaceuticos, which could be worth up to $5 billion.